Our study validates that PRMT6 transcriptionally activates YTHDF2, thereby promoting malignant phenotypes in glioma, a process that depends on PRMT6’s methyltransferase activity (Fig. 8). This evidence concerns the gene PRMT6 and central nervous system cancer.